Avalo Therapeutics (AVTX) Return on Assets (2016 - 2025)
Historic Return on Assets for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to 0.79%.
- Avalo Therapeutics' Return on Assets fell 7200.0% to 0.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79%, marking a year-over-year decrease of 7200.0%. This contributed to the annual value of 0.41% for FY2024, which is 7500.0% up from last year.
- Latest data reveals that Avalo Therapeutics reported Return on Assets of 0.79% as of Q3 2025, which was down 7200.0% from 0.35% recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Return on Assets registered a high of 0.5% during Q1 2025, and its lowest value of 1.97% during Q1 2024.
- Moreover, its 5-year median value for Return on Assets was 0.18% (2024), whereas its average is 0.35%.
- As far as peak fluctuations go, Avalo Therapeutics' Return on Assets tumbled by -16900bps in 2024, and later skyrocketed by 24800bps in 2025.
- Over the past 5 years, Avalo Therapeutics' Return on Assets (Quarter) stood at 0.0% in 2021, then plummeted by -538bps to 0.0% in 2022, then plummeted by -66299bps to 1.26% in 2023, then soared by 78bps to 0.28% in 2024, then plummeted by -181bps to 0.79% in 2025.
- Its Return on Assets was 0.79% in Q3 2025, compared to 0.35% in Q2 2025 and 0.5% in Q1 2025.